Saunders Elijah, Cable Greg, Neutel Joel
Division of Cardiology, Section of Hypertension, University of Maryland School of Medicine. Baltimore, MD, USA.
J Clin Hypertens (Greenwich). 2008 Jan;10(1):27-33. doi: 10.1111/j.1524-6175.2007.07195.x.
The secondary analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) clinical trial investigated whether baseline demographic and clinical variables are predictive of different degrees of blood pressure reduction following an angiotensin II receptor blocker/diuretic treatment regimen. Irbesartan/hydrochlorothiazide and other angiotensin receptor blocker combinations with a diuretic have been shown to be effective in reducing systolic blood pressure in a diverse patient population previously uncontrolled on monotherapy. Ordinary least squares regression analysis was performed on the intent-to-treat population of the INCLUSIVE study to identify variables predictive of variations in blood pressure changes in response to irbesartan/hydrochlorothiazide combination therapy. Higher baseline systolic blood pressure, female sex, type 2 diabetes, and statin therapy were found to be predictive of additional blood pressure lowering with this combination. The impact of higher baseline systolic blood pressure and diabetic state on changes in systolic blood pressure were diminished in female patients compared with male patients. In conclusion, a significant correlation may exist between certain clinical/demographic characteristics and the extent of the therapeutic response with irbesartan/hydrochlorothiazide treatment.
厄贝沙坦/氢氯噻嗪在不同患者群体中降低血压的二次分析（INCLUSIVE）临床试验，研究了基线人口统计学和临床变量是否可预测在接受血管紧张素II受体阻滞剂/利尿剂治疗方案后不同程度的血压降低情况。厄贝沙坦/氢氯噻嗪以及其他血管紧张素受体阻滞剂与利尿剂的组合，已被证明在先前单药治疗未能控制血压的不同患者群体中，能有效降低收缩压。对INCLUSIVE研究的意向性治疗人群进行了普通最小二乘法回归分析，以确定可预测厄贝沙坦/氢氯噻嗪联合治疗后血压变化差异的变量。结果发现，较高的基线收缩压、女性、2型糖尿病和他汀类药物治疗可预测该联合用药能进一步降低血压。与男性患者相比，较高的基线收缩压和糖尿病状态对女性患者收缩压变化的影响较小。总之，某些临床/人口统计学特征与厄贝沙坦/氢氯噻嗪治疗的治疗反应程度之间可能存在显著相关性。
